Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7631792 | 0.88 | CACNA1C (0.35) | CACNA1CPTGS1ESR1PDE4AMEN1 | |
| SCHEMBL7633272 | 0.88 | CACNA1C (0.35) | CACNA1CPTGS1ESR1PDE4AMEN1 | |
| SCHEMBL7628875 | 0.87 | ESR1 (0.33) | CACNA1CPTGS1ESR1PDE4A | |
| SCHEMBL6889653 | 0.87 | CACNA1C (0.34) | CACNA1CPTGS1ESR1PDE4AABCC2 | |
| SCHEMBL6889748 | 0.87 | CACNA1C (0.35) | CACNA1CPTGS1ESR1PDE4A | |
| SCHEMBL6891529 | 0.86 | ESR1 (0.33) | CACNA1CPTGS1ESR1PDE4AABCC2 | |
| SCHEMBL8194895 | 0.84 | FAP (0.47) | — | |
| SCHEMBL7630405 | 0.83 | CACNA1C (0.33) | CACNA1CPTGS1ESR1PDE4A | |
| SCHEMBL7633495 | 0.83 | CACNA1C (0.33) | CACNA1CPTGS1ESR1PDE4A | |
| SCHEMBL7634446 | 0.82 | CACNA1C (0.34) | CACNA1CPTGS1ESR1PDE4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218033-A2 | CATIONIC LIPID COMPOUNDS AND USE THEREOF FOR TRANSFERRING NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST | UNIVERSITE PARIS-NORD (FR) | 2002-07-03 | — | — | EP | claimed |
| WO-2001011068-A2 | CATIONIC LIPID COMPOUNDS AND USE THEREOF FOR TRANSFERRING NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST | UNIVERSITE PARIS NORD (FR) | 2001-02-15 | — | — | WO | claimed |
| EP-1022279-B1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1218033-A2 | CATIONIC LIPID COMPOUNDS AND USE THEREOF FOR TRANSFERRING NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST | UNIVERSITE PARIS-NORD (FR) | 2002-07-03 | — | — | EP | disclosed |
| US-6310056-B1 | 2-SUBSTITUTED WITH A IMIDAZO(5,1-B)THIAZOLE GROUP; TREATING INFECTIONS, INCLUDING ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| WO-2001011068-A2 | CATIONIC LIPID COMPOUNDS AND USE THEREOF FOR TRANSFERRING NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST | UNIVERSITE PARIS NORD (FR) | 2001-02-15 | — | — | WO | disclosed |
| EP-1022279-A1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |